DUBLIN – Mitoconix Bio Ltd., an Israeli startup commercializing science that emerged from Stanford University's School of Medicine, raised $20 million in series A funding to take forward a first-in-class inhibitor of mitochondrial division for treating Huntington's disease and other neurodegenerative conditions.